I 
112TH CONGRESS 
1ST SESSION H. R. 1394 
To establish a comprehensive interagency response to reduce lung cancer 
mortality in a timely manner. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 6, 2011 
Mrs. CHRISTENSEN (for herself and Mr. LOBIONDO) introduced the following 
bill; which was referred to the Committee on Energy and Commerce, and 
in addition to the Committees on Armed Services and Veterans’ Affairs, 
for a period to be subsequently determined by the Speaker, in each case 
for consideration of such provisions as fall within the jurisdiction of the 
committee concerned 
A BILL 
To establish a comprehensive interagency response to reduce 
lung cancer mortality in a timely manner. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Lung Cancer Mortality 
Reduction Act of 2011’’. 
SEC. 2. FINDINGS. 
Congress makes the following findings: 
VerDate Mar 15 2010 
04:24 Apr 08, 2011
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1394.IH
H1394
rfrederick on DSKD9S0YB1PROD with BILLS
(1) Lung cancer is the leading cause of cancer 
death for both men and women, accounting for 28 
percent of all cancer deaths. 
(2) The National Cancer Institute estimates 
that in 2010, there were 222,520 new diagnoses of 
lung cancer and 157,300 deaths attributed to the 
disease. 
(3) According to projections published in the 
Journal of Clinical Oncology in 2009, between 2010 
and 2030, the incidence of lung cancer will increase 
by 46 percent for women and by 58 percent for men. 
The increase in the incidence of lung cancer among 
minority communities during that time period will 
range from 74 percent to 191 percent. 
(4) Lung cancer causes more deaths annually 
than the next 4 leading causes of cancer deaths, 
colon cancer, breast cancer, prostate cancer, and 
pancreatic cancer, combined. 
(5) The 5-year survival rate for lung cancer is 
only 15 percent, while the 5-year survival rate for 
breast cancer is 89 percent, for prostate cancer 99 
percent, and for colon cancer 65 percent. Yet in re-
search dollars per death, lung cancer is the least 
funded of the major cancers. 
VerDate Mar 15 2010 
04:24 Apr 08, 2011
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1394.IH
H1394
rfrederick on DSKD9S0YB1PROD with BILLS
(6) In 2001, the Lung Cancer Progress Review 
Group of the National Cancer Institute stated that 
funding for lung cancer research was ‘‘far below the 
levels characterized for other common malignancies 
and far out of proportion to its massive health im-
pact’’ and it gave the ‘‘highest priority’’ to the cre-
ation of an integrated multidisciplinary, multi-insti-
tutional research program. No comprehensive plan 
has been developed. 
(7) While smoking is the leading risk factor for 
lung cancer, the President’s National Cancer Advi-
sory Board Report of 2010 identified radon as the 
second leading cause of lung cancer and listed 15 
other environmental contaminants strongly associa-
tion with lung cancer, and there is accumulating evi-
dence that hormonal and genetic factors may influ-
ence the onset. 
(8) Lung cancer is the most stigmatized of all 
the cancers and the only cancer blamed on patients, 
whether they smoked or not. 
(9) Nearly 20 percent of lung cancer patients 
have never smoked. Sixty percent of individuals di-
agnosed with lung cancer are former smokers who 
quit, often decades ago. 
VerDate Mar 15 2010 
04:24 Apr 08, 2011
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1394.IH
H1394
rfrederick on DSKD9S0YB1PROD with BILLS
(10) Lung cancer in men and women who never 
smoked is the sixth leading cause of cancer death. 
Of individuals diagnosed with lung cancer who have 
never smoked, 2⁄3 of are women. 
(11) Lung cancer is the leading cause of cancer 
death in the overall population and in every major 
ethnic grouping, including White, African-American, 
Hispanic, Asian and Pacific Islander, American In-
dian, and Alaskan Native, with an even dispropor-
tionately higher impact on African-American males 
that has not been addressed. 
(12) Military personnel, veterans, and muni-
tions workers exposed to carcinogens such as Agent 
Orange, crystalline forms of silica, arsenic, uranium, 
beryllium, and battlefield fuel emissions have in-
creased risk for lung cancer. 
(13) Only 16 percent of lung cancer is being di-
agnosed at an early stage and there were no targets 
for the early detection or treatment of lung cancer 
included in the Department of Health and Human 
Services’s ‘‘Healthy People 2010’’ or ‘‘Healthy Peo-
ple 2020’’. 
(14) An actuarial analysis carried out by 
Milliman Inc. and published in Population Health 
Management Journal in 2009 indicated that early 
VerDate Mar 15 2010 
05:47 Apr 08, 2011
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1394.IH
H1394
rfrederick on DSKD9S0YB1PROD with BILLS
detection of lung cancer could save more than 
70,000 lives a year in the United States. 
(15) A National Cancer Institute study in 2009 
indicated that while the value of life lost to lung can-
cer will exceed $433,000,000,000 a year by 2020, a 
4-percent annual decline in lung cancer mortality 
would reduce that amount by more than half. 
(16) In 2010, the National Cancer Institute re-
leased initial results from the National Lung Screen-
ing Trial, a large-scale randomized national trial 
that compared the effect of low-dose helical com-
puted tomography (‘‘CT’’) and a standard chest x- 
ray on lung cancer mortality. The study found 20 
percent fewer lung cancer deaths among study par-
ticipants screened with the CT scan. 
SEC. 3. SENSE OF THE CONGRESS CONCERNING INVEST-
MENT IN LUNG CANCER RESEARCH. 
It is the sense of the Congress that— 
(1) lung cancer mortality reduction should be 
made a national public health priority; and 
(2) a comprehensive mortality reduction pro-
gram coordinated by the Secretary of Health and 
Human Services is justified and necessary to ade-
quately address all aspects of lung cancer and re-
VerDate Mar 15 2010 
04:24 Apr 08, 2011
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H1394.IH
H1394
rfrederick on DSKD9S0YB1PROD with BILLS
duce lung cancer mortality among current smokers, 
former smokers, and non-smokers. 
SEC. 4. LUNG CANCER MORTALITY REDUCTION PROGRAM. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 399V–6. LUNG CANCER MORTALITY REDUCTION PRO-
GRAM. 
‘‘(a) IN GENERAL.—Not later than 180 days after 
the date of enactment of the Lung Cancer Mortality Re-
duction Act of 2011, the Secretary, in consultation with 
the Secretary of Defense, the Secretary of Veterans Af-
fairs, the Director of the National Institutes of Health, 
the Director of the Centers for Disease Control and Pre-
vention, the Commissioner of Food and Drugs, the Admin-
istrator of the Centers for Medicare & Medicaid Services, 
the Director of the National Center on Minority Health 
and Health Disparities, and other members of the Lung 
Cancer Advisory Board established under section 7 of the 
Lung Cancer Mortality Reduction Act of 2011, shall im-
plement a comprehensive program to achieve a 50-percent 
reduction in the mortality rate of lung cancer by 2020. 
‘‘(b) REQUIREMENTS.—The program implemented 
under subsection (a) shall include at least the following: 
VerDate Mar 15 2010 
04:24 Apr 08, 2011
Jkt 099200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H1394.IH
H1394
rfrederick on DSKD9S0YB1PROD with BILLS
‘‘(1) With respect to the National Institutes of 
Health— 
‘‘(A) a strategic review and prioritization 
by the National Cancer Institute of research 
grants to achieve the goal of the lung cancer 
mortality reduction program in reducing lung 
cancer mortality; 
‘‘(B) the provision of funds to enable the 
Airway Biology and Disease Branch of the Na-
tional Heart, Lung, and Blood Institute to ex-
pand its research programs to include pre-
dispositions to lung cancer, the interrelationship 
between lung cancer and other pulmonary and 
cardiac disease, and the diagnosis and treat-
ment of these interrelationships; 
‘‘(C) the provision of funds to enable the 
National Institute of Biomedical Imaging and 
Bioengineering to expedite the development of 
screening, diagnostic, surgical, treatment, and 
drug testing innovations to facilitate the poten-
tial of imaging as a biomarker and reduce lung 
cancer mortality, such as through expansion of 
the Quantum Grant Program and Image-Guid-
ed Interventions programs of the National In-
VerDate Mar 15 2010 
04:24 Apr 08, 2011
Jkt 099200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H1394.IH
H1394
rfrederick on DSKD9S0YB1PROD with BILLS